Cannabis Hyperemesis Syndrome Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 140 studies associated with Cannabis Hyperemesis Syndrome.
Here is a small sampling of Cannabis Hyperemesis Syndrome studies by title:
- A Case Report on Cannabinoid Hyperemesis Syndrome in Palliative Care: How Good Intentions Can Go Wrong
- Pharmacological management of cannabinoid hyperemesis syndrome: an update of the clinical literature
- Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department
- Changes in Emergency Department Visits for Cannabis Hyperemesis Syndrome Following Recreational Cannabis Legalization and Subsequent Commercialization in Ontario, Canada
- Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes
Components of the Cannabis Hyperemesis Syndrome Research Dashboard
- Dosing information available for Cannabis Hyperemesis Syndrome
- Chemotype guidance for treating Cannabis Hyperemesis Syndrome with cannabis
- Synopsis of cannabis research for Cannabis Hyperemesis Syndrome
- Individual study details for Cannabis Hyperemesis Syndrome
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Cannabinoids & Endocannabinoids
- Study Result
- Year of Publication
Overview - Cannabis Hyperemesis Syndrome
Description of Cannabis Hyperemesis Syndrome
Cannabinoid hyperemesis syndrome [distinct from cyclical vomiting syndrome (CVS)] is a relatively rare condition characterized by incessant abdominal discomforts, nausea, and vomiting that is relieved by taking hot showers. The reason for these symptoms are presently unclear and subject to ongoing research. A number of hypotheses have been proposed including achieving a causative tolerance, interference with the body's temperature mechanism, and the potential presence of various pesticides or chemical residue.
Cannabis Hyperemesis Syn.
Mental and Behavioural Disorders
ICD-10 Code: F12.188
Cannabis Hyperemesis Syndrome Symptoms:
Persistant nausea/vomiting (relieved by long hot showers), abdominal pain, dehydration, weightloss, renal failure
Also known as:
THC Interaction with Pharmaceutical Drugs
- THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example.
- THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin). Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
- Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
CBD Interaction with Pharmaceutical Drugs
- CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
- Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.